The Friday Podcast

Physicians and scientists from Quintiles' Cardiovascular and Metabolic Diseases group and the Diabetes Center of Excellence recently published an extensive review of new diabetes drugs under development. These drugs include more convenient forms of receiving existing drugs, such as oral administration instead of via injection.  They also include a wide array of new classes of drugs, such as glucokinase activators, glucagon receptor antagonists, G-protein coupled receptor agonists, and dual SGLT1/SGLT2 inhibitors. Future marketing approvals of these drugs will facilitate a move towards personalized medicine in this therapeutic area.

About The Author

Director, Cardiovascular and Metabolic Diseases, Medical Strategy & Science, Therapeutic Strategy & Science